Abstract
Oryzanol has been reported to reduce serum total cholesterol (hypolipidemic agent) by inhibiting HMG-CoA reductase, an enzyme responsible for the metabolic pathway that produces cholesterol and isoprenoid. The purpose of this experiment is to determine the inhibition activity of oryzanol derivatives on HMG-CoA reductase by molecular docking. Four structure of oryzanol derivatives, Lanosteryl-ferulate, Brassicasteryl-ferulate, Lupeol-ferulate, and Cholesteryl-ferulate were used as ligands for molecular docking. The HMG-CoA reductase structure was obtained from protein data bank and the study was performed using AutoDock Tools as a molecular docking software. All oryzanol derivatives show binding affinity against HMG-CoA reductase. Lupeol-ferulate was predicted to be the best inhibitory activity against HMG-CoA reductase because of molecular docking.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
